Obicetrapib for dyslipidemia with or without cardiovascular risk: A GRADE ‐assessed meta‐analysis of randomized trials with trial sequential evidence
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70316 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Ahmed Emara und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Al-Azhar University, Cairo, Egypt. Hauptthemen laut MEDLINE: Dyslipidemias, Cardiovascular Diseases, Anticholesteremic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Aims
Obicetrapib, an oral cholesteryl ester transfer protein ( CETP ) inhibitor, has demonstrated potent LDL ‐C lowering in recent phase 2/3 trials. We evaluated Obicetrapib (1, 2.5, 5, and 10 mg) efficacy and safety in adults with dyslipidemia, with or without atherosclerotic cardiovascular disease ( ASCVD ) risk. Materials and Methods We performed a meta‐analysis of randomized controlled trials ( RCTs ) identified through PubMed , Cochrane, Scopus, and Web of Science up to June 2025. Dichotomous outcomes were analyzed as risk ratios ( RRs ) and continuous outcomes as mean differences ( MDs ), both with 95% confidence intervals ( CIs ). PROSPERO ID : CRD420251107076.
Results
Six RCTs including 3399 patients were analysed. Compared with placebo, Obicetrapib significantly reduced LDL ‐C at 8–12 weeks ( MD –27.66 mg/ dL (−26.96%); 95% CI –33.62 to −21.70; p < 0.0001) and non‐ HDL ‐C ( MD –35.41 mg/ dL (−28.08%); 95% CI –39.42 to −31.39; p < 0.0001). It also increased HDL ‐C ( MD 70.85 mg/ dL (141.7%); 95% CI 62.56–79.15; p < 0.0001) and improved achievement of LDL ‐C targets:
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Faculty of Medicine, Menoufia University, Menoufia, Egypt.
- Department of Medicine, An-Najah National University, Nablus, Palestine.
- Faculty of Medicine, Tanta University, Tanta, Egypt.
- Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
- Department of Cardiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Ahmed Emara
Zitieren
APA
Emara, A., Gadelmawla, A. F., Awashra, A., Rifai, M., Elgendy, M. S., Diaa, A., Emara, M., Odat, R. M., Assaassa, A., & Shubietah, A. (2026). Obicetrapib for dyslipidemia with or without cardiovascular risk: A GRADE ‐assessed meta‐analysis of randomized trials with trial sequential evidence. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70316
Vancouver
Emara A, Gadelmawla AF, Awashra A, Rifai M, Elgendy MS, Diaa A, et al. Obicetrapib for dyslipidemia with or without cardiovascular risk: A GRADE ‐assessed meta‐analysis of randomized trials with trial sequential evidence. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70316
BibTeX
@article{Emara2026,
author = {Emara, Ahmed and Gadelmawla, Ahmed Farid and Awashra, Ameer and Rifai, Mohamed and Elgendy, Mohamed S and Diaa, Ahmed and Emara, Mohamed and Odat, Ramez M and Assaassa, Abdalrahman and Shubietah, Abdalhakim},
title = {Obicetrapib for dyslipidemia with or without cardiovascular risk: A GRADE ‐assessed meta‐analysis of randomized trials with trial sequential evidence},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70316}
}
EUVIMED